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OBJECTIVES: To analyze the accuracy of an AMCP budget
impact model designed to forecast the ﬁrst-year use of a new
osteoporosis therapy in a managed care/pharmacy beneﬁt setting
and describe characteristics of patients who initiated therapy.
METHODS: Following AMCP guidelines, a model was devel-
oped to predict ﬁrst-year (2003) use and treatment costs for a
new osteoporosis therapy (teriparatide) using plan characteris-
tics (total number of insured lives, age and sex distribution) 
as model inputs. Using administrative claims data from an
employer database (n = 3.5 million), predicted versus actual use
and treatment costs were compared for eight health care plans
of varying types (indemnity, PPO, POS, HMO). Demographic
characteristics and medical histories of patients initiating the new
therapy were compared to other osteoporosis patients in the
database (ICD-9 CM = 733.0x). RESULTS: The model predicted
a total of 131 patients would initiate therapy; the actual number
was 133. The number was overestimated in four plans with the
margin of error ranging from +113% (34 predicted vs. 16 actual)
to -30% (40 predicted vs. 57 actual). The difference in predicted
versus actual treatment costs ranged from -$19,527 to
+$103,315. Patients initiating the new therapy were on average
older compared to other osteoporosis patients (P < 0.001). In the
year prior to initiating the new therapy, these patients also had
more outpatient, inpatient, ofﬁce, and prescription drug claims
per month and were more likely to have seen a specialist or have
had an osteoporotic fracture compared to other osteoporosis
patients (P < 0.001). CONCLUSION: AMCP-style models for
newly approved therapies can provide important insight to
health plan administrators when making formulary decisions
during the initial year of therapy availability. Updating such
models by incorporating inputs based on patient characteristics
and actual ﬁrst-year use of therapy may yield more accurate esti-
mates of future use and treatment costs.
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OBJECTIVES: Objectives were: 1) to determine the effectiveness
of osteoporosis medications; 2) to identify risk factors and 
other covariates that predict osteoporotic fractures; and 3) to
determine the cost-effectiveness of osteoporosis medications.
METHODS: A retrospective cohort study was conducted using
DOD claims from ﬁscal years 2000 to 2003. Using an intent-to-
treat study design, a total of 49,851 women >= age 50 were fol-
lowed. Differences in effectiveness (fracture/no fracture) were
determined by both logistic and direct Cox proportional hazard
regressions. To assess cost-effectiveness, a net-beneﬁt regression
method was employed. RESULTS: Findings showed that the
three-year cumulative incidence of an osteoporotic fracture in
this cohort was 2.5% (0.4% in patients without an osteoporo-
sis diagnosis; 6.1% in patients with an osteoporosis diagnosis).
The medication effectiveness results obtained from both regres-
sion models were consistent and suggested that women treated
with the combination of alendronate and HRT were at lower
risk for any fracture, hip fracture, and vertebral fracture when
compared to no treatment, while comparisons of the individual
medications with no treatment did not show a signiﬁcant
decrease in risk. Variables that signiﬁcantly increased the risk of
fracture were: prior fracture, increasing age, and oral corticos-
teroid use >= year. The net-beneﬁt regression showed that the use
of osteoporosis medications was not cost-effective overall in the
short-term compared to no treatment. However, among high-risk
populations, such as patients with a prior osteoporotic fracture
or those >= 65, medications became more cost-effective. CON-
CLUSIONS: Combination therapy with HRT and alendronate
was more effective than no treatment in DOD women >= 50.
None of the treatment options were cost-effective in the short-
term for the overall population, but some were more cost-
effective in subsets of high-risk patients. The results of this study
were potentially inﬂuenced by the presence of selection bias,
therefore propensity scoring will be conducted.
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OBJECTIVES: To estimate the cost-effectiveness of bisphospho-
nates (Alendronate, Risedronate and cyclical Etidronate) or
Raloxifene versus no therapy over a two-year treatment period
in patients with osteoporosis and in those with previous fragility
fracture. METHODS: A decision analytic model using local cost
data and clinical data from meta-analysis or randomised con-
trolled trial was developed to evaluate cost-effectiveness of the
various interventions. The main perspective of the economic
evaluation was that of health care purchaser. Therefore, only
direct health care costs were considered in the evaluation. A 
two-year time horizon was chosen as clinical data about the efﬁ-
cacy of the various interventions considered are available.
RESULTS: The results of the evaluation showed that it is not
cost-effective to treat all patients. However, the analysis per-
formed did not consider indirect and intangible cost due to 
the perspective used in the evaluation. Alendronate and cyclical
etidronate appeared to be the most cost-effective agents to
prevent hip fracture and vertebra fracture respectively. The
ranking and magnitude of the incremental cost-effectiveness
ratio of the various treatments did not change by the sensitivity
analyses using the 95% CI of the efﬁcacy data. CONCLUSION:
If treatment is indicated, it would be prudent to consider cycli-
cal etidronate if the risk of hip fracture is low. Raloxifene can
be considered if patient will beneﬁt from other non-osteoporo-
sis indication in this group of patients. However, in patients who
have high risk of hip fracture, alendronate or risedronate will be
more cost-effective.
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PATIENTS
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OBJECTIVES: Male osteoporosis is traditionally under-
diagnosed. In the US, two-million men have osteoporosis and
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another 3.6 million are at an increased risk. In men over 64 years
of age, 80% of hip fractures are attributed to osteoporosis,
costing a national direct expenditure of $13.8 billion in 2000.
Earliest diagnosis is through a bone density test, which could
help in prevention of hip fractures and signiﬁcant savings in
health care costs. This study examines the various physician and
patient factors, which inﬂuence the bone density test prescribing
for osteoporosis in male ambulatory patients. METHODS:
Patient factors such as age, race, geographical location and
payment source, and Physician factors such as specialty and
referral status were used to determine their inﬂuence on the
number of bone density tests prescribed. Data from the National
Ambulatory Medical Care Survey (NAMCS) 2002 were utilized.
Male patients with principal diagnosis of osteoporosis (ICD-9-
CM code 733.00) with age more than or equal to 50 years were
analyzed using multiple linear and binomial logit regression
models. RESULTS: The number of bone density tests performed
were independent of patients’ geographic region (R2 = 0.111).
White patients were prescribed more bone density tests com-
pared to other races (R2 = 0.436). Patients above 75 years of age
and patients with Federal source of payments were prescribed
more bone density tests than other patients (R2 = 0.345).
Numbers of bone density tests were not inﬂuenced by whether
the patient was referred (R2 = 0.027). Family Practice physicians
prescribed more bone density tests compared to other specialties
(R2 = 0.326). CONCLUSIONS: The numbers of bone density
tests prescribed are signiﬁcantly inﬂuenced by patients’ race, age
and source of payments, and physician’s specialty. Bone density
screening for men over 50 years of age appears to be an optimal
approach to manage osteoporosis in men.
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OBJECTIVES: A preexisting fracture is a very strong predictor
of subsequent osteoporotic fractures, emphasizing the need to
aggressively treat patients with existing osteoporotic fractures.
The objectives of the study are to examine the prevalence of drug
treatment and factors associated with drug treatment among
elderly nursing home (NH) admissions with an indication of
osteoporotic fracture. METHODS: The Minimum Data Set for
Nursing Home Assessment and Care Screening (MDS) Version
2.0 and physicians’ medication orders from 1999 were utilized
for this study. The outcome was the use of anti-osteoporotic drug
therapy at NH admission. Independent variables included
patient demographics, comorbidities, functional capabilities
(activities of daily living or ADLs), and cognitive performance
(MDS-COGS). Multivariate analysis was conducted using logis-
tic regression with Generalized Estimating Equations (GEE) to
adjust for clustering within NH facilities. RESULTS: A total of
2673 NH residents were identiﬁed with documentation of osteo-
porotic fracture within 180 days or affecting current care at
admission; however, only 642 (24.02%) received anti-osteo-
porotic drug therapy at admission. Gender (p < 0.0001), age (p
= 0.0394), and functional capabilities (p = 0.0002) were signiﬁ-
cantly associated with the use of anti-osteoporotic drug. Non-
signiﬁcant factors were region, race, education, comorbidity and
cognition. Treatment was less likely for male residents (OR:
0.45; 95% CI, 0.33–0.62) and residents older than 85 (OR: 0.79;
95% CI, 0.67–0.97). Those who were independent in terms of
ADLs were more likely to receive drug treatment (OR: 2.54;
95% CI, 1.27–5.07), compared to those who were fully depen-
dent. CONCLUSIONS: While osteoporotic fracture is common
among the NH elderly population, the majority remained
untreated. Increasing age was inversely related to receipt of anti-
osteoporotic drugs. Female elderly and those with fewer limita-
tions in daily activities were more likely to receive drug therapy
for osteoporosis.
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OBJECTIVE: To evaluate the impact of an osteoporosis therapy
intervention program in a health plan setting. METHODS: A
clinical team of pharmacists, obstetricians/gynecologists and
endocrinologists designed and implemented an educational ini-
tiative for physicians and members. Medical and pharmacy
claims data for female enrollees over the age of 40 were retrieved
for the time period of July, 2002 through June, 2003. Criteria
for targeted patients included a fracture history (deﬁned by ICD-
9 and CPT codes) and negative history of estrogen/progestin use
over the 1-year period, and four-month negative history of osteo-
porosis therapy (alendronate, risedronate, calcitonin, raloxifene,
or teriparatide). Physicians received a patient list, an educational
tool for management of osteoporosis and coupons for a free ﬁrst-
month supply of a bisphosphonate. Targeted members received
a 17-page handbook highlighting drug treatment, lifestyle mod-
iﬁcations, and information regarding prescription drug discount
programs. The impact of the intervention was analyzed using
pharmacy claims data for eligible patients with pharmacy bene-
ﬁts. Primary outcome measure was deﬁned as the percent of
patients with a claim for an osteoporosis agent at three, six, and
nine-months post-intervention. Additionally, a member survey
was conducted six-months post-intervention to evaluate the
member mailing. RESULTS: There were 1612 program partici-
pants. At three, six and nine-months respectively, 3.76%
(32/852), 5.12% (40/781) and 5.97% (42/704) of eligible
patients had a claim for an osteoporosis agent. A 23% survey
response rate was achieved (364/1612). Survey results indicated
18% of responders were taking prescription osteoporosis med-
ications at that time. Post-intervention, 19% of the responders
made a doctor appointment, 15% attended the appointment,
17% received a prescription, 13% received medication samples,
and 11% ﬁlled the prescription. CONCLUSION: Survey results
indicate higher rate of medication use compared to claims data-
base analysis, which does not capture medication sampling.
Another mailing has been done to continue to improve osteo-
porosis care.
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OBJECTIVE: Several features of bisphosphonate therapy for
osteoporosis may inﬂuence patient satisfaction, including dosing
convenience. The objective of this study was to evaluate the psy-
chometric characteristics of the Osteoporosis Patient Satisfaction
Questionnaire (OPSAT-Q), which assesses patient satisfaction
with osteoporosis treatment. METHODS: Patient focus groups
and cognitive debrieﬁngs informed the development of the 16-
item OPSAT-Q, which contains four subscales: Convenience,
Conﬁdence with Daily Activities, Side Effects and Overall Satis-
